Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares

Rhea-AI Filing Summary

Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-withholding transaction tied to equity compensation. On April 14, 2026, 946 shares of Common Stock were withheld by the company at $4.91 per share to cover tax obligations from previously granted restricted stock units vesting. After this withholding, Muzzey directly holds 326,310 shares of Myriad Genetics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Muzzey Dale

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	946	$4.91	$5K

Holdings After Transaction: Common Stock — 326,310 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 946 shares Withholding price per share: $4.91 per share Shares held after transaction: 326,310 shares

3 metrics

Shares withheld for taxes 946 shares Tax-withholding disposition on April 14, 2026

Withholding price per share $4.91 per share Based on closing price on April 14, 2026

Shares held after transaction 326,310 shares Direct holdings following tax withholding

Key Terms

restricted stock units, tax withholding obligations, Common Stock, closing price

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units previously granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy tax withholding obligations in connection"

Common Stock financial

"Represents shares of Common Stock withheld by the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

closing price financial

"determined based on the closing price of Issuer's Common Stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muzzey Dale

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2026		F		946(1)	D	$4.91	326,310	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.

Remarks:

	By: Justin Hunter For: Dale Muzzey	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Myriad Genetics (MYGN) report for Dale Muzzey?

Myriad Genetics reported that Chief Scientific Officer Dale Muzzey had 946 shares of Common Stock withheld to cover tax obligations from vesting restricted stock units, rather than executing an open-market sale, as disclosed in a Form 4 insider transaction.

Was the Myriad Genetics (MYGN) Form 4 a stock sale by the CSO?

No, the Form 4 shows a tax-withholding disposition. The company withheld 946 shares at $4.91 per share to satisfy Muzzey’s tax obligations on RSUs vesting, instead of him selling shares on the open market.

How many Myriad Genetics (MYGN) shares does Dale Muzzey hold after the transaction?

After the tax-related withholding of 946 shares, Chief Scientific Officer Dale Muzzey directly holds 326,310 shares of Myriad Genetics Common Stock, as reported in the Form 4 insider filing for April 14, 2026.

What price was used for the Myriad Genetics (MYGN) tax-withholding shares?

The 946 shares withheld for taxes were valued at $4.91 per share. The filing states this number of shares was determined using the closing price of Myriad Genetics Common Stock on April 14, 2026.

What triggered the tax withholding in the Myriad Genetics (MYGN) Form 4?

The tax withholding was triggered by the vesting of restricted stock units previously granted to Dale Muzzey. To satisfy related tax obligations, Myriad Genetics withheld 946 shares instead of requiring a separate cash payment.